Clinical Trial: Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07842445) titled 'Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.' on July 23.

Brief Summary: This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.

Study Start Date: Dec. 01, 2026

Study Type: INTERVENTIONAL

Condition: Solid Tumor (Phase I) Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Intervention: DRUG: GNTbm-38

Phase 1a is the dose escalation phase to firstly determine the MTD of patients with solid tumor. Once MTD for ...